Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EPS (Weighted Average and Diluted) (2016 - 2025)

Corcept Therapeutics' EPS (Weighted Average and Diluted) history spans 10 years, with the latest figure at $0.2 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 20.0% year-over-year to $0.2; the TTM value through Dec 2025 reached $0.82, down 33.33%, while the annual FY2025 figure was $0.82, 33.33% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.2 at Corcept Therapeutics, up from $0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.41 in Q3 2024 and bottomed at $0.14 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.24 (2021), against an average of $0.24.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 100.0% in 2023 before it plummeted 60.98% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.26 in 2021, then tumbled by 46.15% to $0.14 in 2022, then skyrocketed by 100.0% to $0.28 in 2023, then decreased by 10.71% to $0.25 in 2024, then decreased by 20.0% to $0.2 in 2025.
  • Per Business Quant, the three most recent readings for CORT's EPS (Weighted Average and Diluted) are $0.2 (Q4 2025), $0.16 (Q3 2025), and $0.29 (Q2 2025).